SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-076314
Filing Date
2023-06-29
Accepted
2023-06-29 16:06:11
Documents
12
Period of Report
2023-06-24
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2320161d1_8k.htm   iXBRL 8-K 27878
  Complete submission text file 0001104659-23-076314.txt   202867

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA blph-20230624.xsd EX-101.SCH 3236
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE blph-20230624_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE blph-20230624_pre.xml EX-101.PRE 22365
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2320161d1_8k_htm.xml XML 3614
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Filer) CIK: 0001600132 (see all company filings)

IRS No.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36845 | Film No.: 231057423
SIC: 2834 Pharmaceutical Preparations